Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Secondary Prophylaxis of Neutropenia in Ovarian Cancer
NCT03858166Phase 4Terminated
- Sponsor
- Shandong University
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegfilgrastim in neutropenia, sponsored by Shandong University. Started Dec 2017; status: terminated.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03858166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858166.